Today at the joint meeting of the International Society of Magnetic Resonance in Medicine (ISMRM) and the European Society of Magnetic Resonance in Medicine and Biology (ESMRMB), GE Healthcare, a leading provider of MRI systems, and CorTechs Labs, a leading medical software innovator providing solutions for quantitative brain volume analysis, are pleased to announce the signing of a strategic joint-marketing agreement. The companies will collaborate to co-market a powerful MRI scanning solution combined with NeuroQuant, CorTechs Labs’ leading MRI post-processing application.
NeuroQuant enables the acquisition of volumetric brain image data and automatically conducts accurate and consistent measurements of cortical and subcortical volumes targeted at identifying evidence of neurodegeneration. This innovative solution will provide neurologists and radiologists with objective support for their clinical impression.
“Accurate measurement of volumes of different parts of the brain may be a useful aid in the diagnosis of neurodegenerative diseases such as Alzheimer’s, multiple sclerosis and traumatic brain injury" said Chris Airriess, chief technology officer, CorTechs Labs. "Volume changes in certain brain structures have been linked in the literature to early indications of such conditions where more traditional diagnoses lack detection sensitivity.” NeuroQuant does this in an automated fashion, without user intervention, and is the only 510(k) approved software for this application.
“CorTechs Labs is a pioneer and a trendsetter in the area of software for the aid of brain diagnostics and is widely used in clinical practices worldwide,” said Baldev Ahluwalia, premium segment manager at GE Healthcare, MRI. “We at GE Healthcare look forward to collaborating with CorTech Labs, benefitting from their innovative approach to providing the highly-desired quantitative brain volumetric information with NeuroQuant.”
"We're pleased to expand our relationship with GE Healthcare. With a leading global presence in advanced MRI scanning solutions, GE Healthcare is a terrific collaborator providing complementary products and services,” said Guri Stark, CorTechs Labs’ CEO. “We look forward to working with GE Healthcare to empower clinicians with objective quantitative data, while continuing NeuroQuant’s growth momentum. In turn, this furthers our vision to establish NeuroQuant as the standard measurement solution for all brain disorders, including Alzheimer’s disease, epilepsy, multiple sclerosis and traumatic brain injury".
About CorTechs Labs
CorTechs Labs develops and markets cutting-edge brain imaging solutions used by neurologists and radiologists in hundreds of clinics and research centers around the world. CorTechs' flagship product, NeuroQuant, is a breakthrough, 510(k) cleared software medical device that makes quantitative analysis of MRI images of the human brain a routine part of clinical practice. As the only FDA cleared medical device capable of automatically detecting and quantifying atrophy in the human brain, NeuroQuant® brings sophisticated, accurate, and fully automated MRI post-processing capabilities to the physician's desktop or mobile device. This provides neurologists, radiologists, and clinical researchers with a convenient and cost-effective means to quantify atrophy of brain structures to help diagnose a variety of brain disorders, including conditions such as Alzheimer's disease, epilepsy, multiple sclerosis and traumatic brain injury.
About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients.
GE Healthcare’s Commitment to Neurology
Between 2010 and 2020, GE Healthcare plans to invest over $500 million in research into neurological disorders. The investment crosses all lines of GE Healthcare's global business and focuses on developing new neurology diagnostic solutions, educating consumers, and expanding research already in progress. Target areas include diagnosing post-traumatic stress disorder, Alzheimer's disease, Parkinson's disease, multiple sclerosis, stroke, concussion and traumatic brain injury. For decades, GE Healthcare has produced diagnostics scanners, imaging agents and software to help physicians see more clearly inside the brain and aid better patient management. In 2013, a $60 million investment with National Football League to develop new MR technology for traumatic brain injury was announced, including a $20 million Global Challenge to advance diagnosis and prognosis of mild TBI.
Media Contact: Shelly Adams - CorTech Labs
E: sadams[.]cortechslabs.com - P: +1 858-459-9704